Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (371-380 of 525) with videos related to

Pageof 53
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 2, 2025
Hydrogel formulations for sustained-release of broadly neutralizing antibodiesCarolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
Vaccine|June 8, 2021
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trialJoel V Chua, Charles Davis, Jennifer S Husson, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
Journal of Virology|May 9, 2014
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activitiesJustin Pollara, Mattia Bonsignori, M Anthony Moody, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
Science Translational Medicine|April 29, 2016
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineagesRuijun Zhang, Laurent Verkoczy, Kevin Wiehe, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Engineering Sustained-Release Broadly Neutralizing Antibody FormulationsCarolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Journal of Virology|July 24, 2015
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1Justin Pollara, Erin McGuire, Genevieve G Fouda, et al.
Pageof 53

Showing results (371-380 of 525) with videos related to

Sort By:
Pageof 53
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 2, 2025
Hydrogel formulations for sustained-release of broadly neutralizing antibodiesCarolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
Vaccine|June 8, 2021
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trialJoel V Chua, Charles Davis, Jennifer S Husson, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
Journal of Virology|May 9, 2014
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activitiesJustin Pollara, Mattia Bonsignori, M Anthony Moody, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
Science Translational Medicine|April 29, 2016
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineagesRuijun Zhang, Laurent Verkoczy, Kevin Wiehe, et al.
PLOS Global Public Health|April 11, 2025
ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boostLeigh H Fisher, Erica Lazarus, Chenchen Yu, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Engineering Sustained-Release Broadly Neutralizing Antibody FormulationsCarolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Journal of Virology|July 24, 2015
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1Justin Pollara, Erin McGuire, Genevieve G Fouda, et al.
Pageof 53